Royal Bank Of Canada Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price upped by Royal Bank Of Canada from $696.00 to $737.00 in a report issued on Friday morning,Benzinga reports. They currently have a sector perform rating on the biopharmaceutical company’s stock.

REGN has been the subject of several other reports. Citigroup downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $900.00 to $700.00 in a report on Monday, May 18th. Wells Fargo & Company raised their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research report on Friday. BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Leerink Partners restated a “market perform” rating and issued a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a report on Monday, May 18th. Finally, Canaccord Genuity Group lowered their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $794.83.

Regeneron Pharmaceuticals Stock Up 3.3%

Shares of NASDAQ REGN opened at $762.63 on Friday. Regeneron Pharmaceuticals has a 52-week low of $541.00 and a 52-week high of $821.11. The firm has a market capitalization of $80.63 billion, a price-to-earnings ratio of 18.85, a PEG ratio of 29.50 and a beta of 0.24. The stock has a 50 day moving average price of $643.13 and a 200 day moving average price of $711.70. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.96 and a current ratio of 4.29.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same period in the previous year, the company posted $12.81 EPS. Regeneron Pharmaceuticals’s revenue was up 16.7% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals will post 2.06 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be given a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.29%.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. This trade represents a 1.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Wedge Capital Management L L P NC lifted its stake in shares of Regeneron Pharmaceuticals by 20.3% during the second quarter. Wedge Capital Management L L P NC now owns 47,775 shares of the biopharmaceutical company’s stock worth $29,790,000 after buying an additional 8,063 shares during the period. Insight Wealth Strategies LLC increased its position in shares of Regeneron Pharmaceuticals by 26.9% in the 2nd quarter. Insight Wealth Strategies LLC now owns 8,734 shares of the biopharmaceutical company’s stock valued at $5,456,000 after acquiring an additional 1,850 shares during the period. Tema ETFs LLC increased its position in shares of Regeneron Pharmaceuticals by 2.3% in the 2nd quarter. Tema ETFs LLC now owns 5,481 shares of the biopharmaceutical company’s stock valued at $3,418,000 after acquiring an additional 121 shares during the period. E. Ohman J or Asset Management AB raised its stake in Regeneron Pharmaceuticals by 35.2% in the 2nd quarter. E. Ohman J or Asset Management AB now owns 3,840 shares of the biopharmaceutical company’s stock worth $2,394,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Harrell Investment Partners LLC raised its stake in Regeneron Pharmaceuticals by 1.3% in the 2nd quarter. Harrell Investment Partners LLC now owns 2,089 shares of the biopharmaceutical company’s stock worth $1,303,000 after acquiring an additional 27 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q2 results substantially exceeded expectations. Regeneron reported non-GAAP EPS of $14.29 versus the $10.16 consensus and revenue of $4.29 billion versus estimates of $3.82 billion. Revenue rose 16.7% year over year. Growth was led by record Dupixent sales, which increased 38%, and U.S. EYLEA HD sales, which jumped 52% to $596 million. Regeneron Q2 2026 Results
• Positive Sentiment: Several analysts raised their price targets after the report. Cantor Fitzgerald lifted its target to $795 and maintained an overweight rating, while Truist raised its target to $772 and reiterated buy. These targets imply additional upside based on the referenced current price. Analyst Price Target Updates
• Neutral Sentiment: Analyst sentiment remains mixed. Morgan Stanley raised its target to $758 and RBC to $737, but both maintained equal-weight or sector-perform ratings. Wells Fargo also raised its target to $750 while keeping an equal-weight rating, suggesting limited conviction despite the earnings beat. Analyst Price Target Updates
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable August 31 to shareholders of record August 18. The approximately 0.5% yield is modest and is unlikely to be a major stock catalyst.
• Negative Sentiment: Multiple law firms publicized a securities class action against Regeneron and its executives. The litigation alleges investors were misled about the protocol and prospects of the Phase 3 fianlimab-Libtayo melanoma trial, which ultimately failed and was associated with an approximately $11 billion market-cap loss. The September 14, 2026 lead-plaintiff deadline and continuing legal notices could pressure sentiment and create potential financial and reputational risks. Regeneron Securities Class Action

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.